These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 18066142)

  • 41. Dietary supplement adverse event reports: review and analysis.
    Talati AR; Gurnani AK
    Food Drug Law J; 2009; 64(3):503-13. PubMed ID: 19999641
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmaceutical postmarket review: fact or fiction?
    Schanz SJ
    Food Drug Law J; 2007; 62(3):493-500. PubMed ID: 17915391
    [No Abstract]   [Full Text] [Related]  

  • 43. Re-examining our approach to the approval and use of new drugs.
    Lee SK
    CMAJ; 2006 Jun; 174(13):1855. PubMed ID: 16785460
    [No Abstract]   [Full Text] [Related]  

  • 44. Adverse drug reaction active surveillance: developing a national network in Canada's children's hospitals.
    Carleton B; Poole R; Smith M; Leeder J; Ghannadan R; Ross C; Phillips M; Hayden M
    Pharmacoepidemiol Drug Saf; 2009 Aug; 18(8):713-21. PubMed ID: 19507171
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The drug safety system conundrum.
    Tiedt TN
    Food Drug Law J; 2007; 62(3):547-558. PubMed ID: 17915396
    [No Abstract]   [Full Text] [Related]  

  • 46. Post-marketing management of the use of non-narcotic analgesics.
    Miettinen OS
    Med Toxicol; 1986; 1 Suppl 1():125-7. PubMed ID: 3821427
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Regulatory decisions and consumers.
    Rawlins MD
    Med Toxicol; 1986; 1 Suppl 1():128-9. PubMed ID: 3821428
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy of natural health products in treating osteoporosis: what is the quality of internet patient advice?
    Whelan AM; Jurgens TM; Bowles SK; Doyle H
    Ann Pharmacother; 2009 May; 43(5):899-907. PubMed ID: 19417114
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adverse drug reactions in elderly patients: alternative approaches to postmarket surveillance.
    Noah BA; Brushwood DB
    J Health Law; 2000; 33(3):383-454. PubMed ID: 11184355
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Herbal medicines: challenges in the modern world. Part 4. Canada and United States.
    Job KM; Kiang TK; Constance JE; Sherwin CM; Enioutina EY
    Expert Rev Clin Pharmacol; 2016 Dec; 9(12):1597-1609. PubMed ID: 27644147
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Drug safety. Gaps in the safety net.
    Couzin J
    Science; 2005 Jan; 307(5707):196-8. PubMed ID: 15653480
    [No Abstract]   [Full Text] [Related]  

  • 52. Vioxx's history and the need for better procedures and better testing.
    Gilhooley M
    Seton Hall Law Rev; 2007; 37(4):941-68. PubMed ID: 18363218
    [No Abstract]   [Full Text] [Related]  

  • 53. Biosimilars--global issues, national solutions.
    Knezevic I; Griffiths E
    Biologicals; 2011 Sep; 39(5):252-5. PubMed ID: 21924623
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Study of natural health product adverse reactions (SONAR): active surveillance of adverse events following concurrent natural health product and prescription drug use in community pharmacies.
    Vohra S; Cvijovic K; Boon H; Foster BC; Jaeger W; LeGatt D; Cembrowski G; Murty M; Tsuyuki RT; Barnes J; Charrois TL; Arnason JT; Necyk C; Ware M; Rosychuk RJ
    PLoS One; 2012; 7(9):e45196. PubMed ID: 23028841
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Consumers of natural health products: natural-born pharmacovigilantes?
    Walji R; Boon H; Barnes J; Austin Z; Welsh S; Baker GR
    BMC Complement Altern Med; 2010 Feb; 10():8. PubMed ID: 20184759
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Regulatory anticipation of postmarket safety problems for novel medicines approved by the EMA between 2001 and 2010: a cross-sectional study.
    Zeitoun JD; Lefèvre JH; Downing NS; Bergeron H; Ross JS
    Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):687-94. PubMed ID: 26554874
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Official experimental testing of biomedical products. Regulatory frame and importance of for quality, safety and efficacy].
    Vieths S; Seitz R
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Oct; 57(10):1133-8. PubMed ID: 25123139
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Postmarket safety in Canada: are significant therapeutic advances and biologics less safe than other drugs? A cohort study.
    Lexchin J
    BMJ Open; 2014 Feb; 4(2):e004289. PubMed ID: 24549164
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Reform Act on safety of drug and health products in France: announcement effect, strengthening or upheaval?].
    Maillols-Perroy AC; Tillet Y
    Therapie; 2012; 67(1):1-10. PubMed ID: 22487499
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Natural Health Products and Diabetes: A Practical Review.
    Necyk C; Zubach-Cassano L
    Can J Diabetes; 2017 Dec; 41(6):642-647. PubMed ID: 28826695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.